FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the field of medicine and pharmaceutics, namely, to a method for the treatment of a malignant neoplasm in an individual, where the method includes conducting TUSC2 therapy in an individual, where at least one immune checkpoint inhibitor has been injected or is being injected to an individual, additionally including the injection of at least one immune checkpoint inhibitor to an individual, where at least one immune checkpoint inhibitor contains an anti-PD1 antibody; to a set for the treatment of a malignant neoplasm containing a therapeutic agent TUSC2 and an immune checkpoint inhibitor, which is an anti-PD1 antibody; and to a composition for the treatment of a malignant neoplasm containing a therapeutic TUSC2 and an immune checkpoint inhibitor, which is an anti-PD1 antibody, in the amount that is therapeutically effective for the treatment of a malignant neoplasm.
EFFECT: group of inventions provides a synergetic effect in the combined therapy of malignant neoplasms.
38 cl, 40 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF | 2015 |
|
RU2743657C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| METHOD OF PRODUCING GENETICALLY MODIFIED LINES OF CELLS OF NATURAL KILLERS WITH KNOCKOUT PD-1 GENE AND HIGH EXPRESSION OF PROTEINS OF FAMILY OF TUMOUR NECROSIS FACTOR FOR IMMUNOTHERAPY OF ONCOLOGICAL DISEASES | 2019 |
|
RU2731293C1 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
